AlloVir (NASDAQ:ALVR) Stock Price Down 4.8% – Time to Sell?

AlloVir, Inc. (NASDAQ:ALVR) dropped 4.8% during trading on Tuesday . The company traded as low as $6.58 and last traded at $6.88. Approximately 146,023 shares changed hands during mid-day trading, an increase of 811% from the average daily volume of 16,030 shares. The stock had previously closed at $7.23.

AlloVir Price Performance

The company has a market cap of $34.70 million, a PE ratio of -0.34 and a beta of 0.63. The company’s 50 day simple moving average is $9.17 and its two-hundred day simple moving average is $12.04.

Hedge Funds Weigh In On AlloVir

Hedge funds have recently made changes to their positions in the stock. Squarepoint Ops LLC purchased a new position in shares of AlloVir during the fourth quarter worth $142,000. Jane Street Group LLC lifted its position in shares of AlloVir by 47.8% during the fourth quarter. Jane Street Group LLC now owns 123,159 shares of the company’s stock worth $52,000 after purchasing an additional 39,808 shares in the last quarter. Northern Trust Corp boosted its stake in shares of AlloVir by 0.8% in the fourth quarter. Northern Trust Corp now owns 159,685 shares of the company’s stock valued at $67,000 after purchasing an additional 1,267 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of AlloVir in the fourth quarter valued at approximately $31,000. Finally, Woodline Partners LP acquired a new stake in AlloVir during the 4th quarter worth approximately $190,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

AlloVir Company Profile

AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.